• Eagle Pharmaceuticals’ Vasopressin ANDA Accepted for Filing by the FDA biospace
    April 17, 2018
    Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or “the Company”) today announced that it has submitted and the U.S. Food and Drug Administration (FDA) has accepted for filing its abbreviated new drug application (ANDA) for vasopressin injection, 1ml.
PharmaSources Customer Service